Dustri Online Services

Books: 0	Journals: 4	Articles: 6

Abstract

Y. Xiao, Y. Lu, Z. Kang, F. Hou, S. Wang, T. Li, Y. Liu and Y. Xia

Institute of Clinical Pharmacology, First Hospital, Peking University, Beijing, China
Objective: To evaluate the tolerability and pharmacokinetics characteristics of antofloxacin hydrochloride, a fluoroquinolone developed in China, after multiple oral doses in healthy male Chinese volunteers. Methods: 13 subjects took 300 mg of antofloxacin hydrochloride once daily for 7 days. Safety was evaluated on Days 0, 2, 4 and 8. Blood and urine samples for pharmacokinetics analysis were taken at designated time points. HPLC was used to assay the serum and urine concentration of antofloxacin. Results: A total of 12 subjects completed the trial and 1 volunteer was dropped because of a skin rash 2 h after the drug was administered. 1 volunteer had a prolonged prothrombin time (PT), another had a serum alanine aminotransferase (ALT) elevation and a third had increases in aspartate aminotransferase (AST) and γ-glutamyltransferase (γ-GT). No other complaints were reported during the trial. The steady state serum concentration on a daily 300 mg oral dose was obtained at 96 h. The pharmacokinetics parameters at steady state were: tmax 1.19 ± 0.59 h, Cmax 4.49 ± 0.81 mg/l, Cmin 1.35 ± 0.33 mg/l, AUCss 74.74 ± 12.58 mg/l × h, Cav 3.11 ± 0.52 mg/l, t1/2β 20.75 ± 2.93 h, PTF 102.13 ± 23.92%. The urinary elimination of antofloxacin over 120 h after the last dose was approximately 62%. Cmax in steady state was 50% higher compared to data for Day 1 after a single dose administration. Conclusions: The results indicated that 300 mg antofloxacin hydrochloride once daily oral administration is safe, but can lead to high drug concentrations. This should be evaluated further.Correspondence to:
Y. Xiao, MD, PhD; Institute of Clinical Pharmacology, Peking University, 38#, Xueyuan Road, Haidian District, Beijing, 100083, China
Email: [email protected]

Abstract

H. Zhao, H. Yu, Y. Liu, Y. Wang and W. Cai

¹Department of Neurosurgery, ²Congenital Malformation Laboratory, Department of Pediatric Surgery, The Second Affiliated Hospital (Shengjing Hospital), China Medical University, ³Department of Neurosurgery, The First Affiliated Hospital, China Medical University, Shenyang, China
Objective: DNA topoisomerase II-α (Topo-IIα) is the inducible form of the enzyme responsible for the first step in the modification of DNA topology. Topo-IIα upregulation has been demonstrated in different tumors. Topo-IIα products may modulate tumoral growth, metastasis and immunosuppression, inhibit apoptosis and cause resistance to chemotherapy. Moreover, the antitumoral effect of Topo-IIα inhibitors has been documented. Material and methods: We studied the immunohistochemical expression and the prognostic value of Topo-IIα on 57 surgical specimens of glioma. Furthermore, we evaluated the correlation between the immunohistochemical expression of Topo-IIa and proliferating cell nuclear antigen (PCNA). Results: A statistically significant correlation with survival time was found, there was no statistically significant difference in survival between patients receiving or not receiving carmustine-based combined chemotherapy (p > 0.05), regardless of histological type. A significant correlation between Topo-IIα and PCNA was documented (r = 0.9245, p < 0.001). Conclusions: Our findings show that gliomas immunohistochemically express Topo-IIa that is correlated with PCNA expression, and which is significantly less frequent in long survivors. The presence of a statistical correlation with survival time and tumor histological grade encourages further studies on a larger series to verify the prognostic value of Topo-IIα expression in gliomas.
Correspondence to:
W. Cai, MD; Congenital Malformation Laboratory, Department of Pediatric Surgery, The Second Affiliated Hospital (Shengjing Hospital), China
Medical University, 36 Sanhao Street, Heping District, Shenyang, China, 110004
Email: [email protected]

Abstract

Q. Li, J.-C. Zhou and Z.-Y. Liu

Abstract

International Journal of Clinical Pharmacology and Therapeutics, Vol. 48 – No. 12/2010 (798-802)

Atorvastatin-induced acute elevation of hepatic enzymes and the absence of cross-toxicity of pravastatin

Y. Liu¹, Z. Cheng¹, L. Ding¹, F. Fang¹, K.-A. Cheng¹, Q. Fang¹ and G.-P. Shi²

¹Department of Cardiology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy Of Medical Sciences, Beijing, China, and ²Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA
Atorvastatin has been associated with liver injury. We reported here two cases of aminotransferases elevation within 12 h of low-dose atorvastatin therapy. Liver functions were fully recovered to the baseline level 11 days after discontinuation of atorvastatin treatment. The possible relative risk factors included advanced age, chronic and systemic diseases, and co-administration of cytochrome P450 3A (CYP3A) enzyme-dependent metabolic drugs or its inhibitors such as clopidogrel and diltiazem. No significant transaminase elevation was observed after switching to pravastatin. Thus, pravastatin might be safer than atorvastain in patients with chronic or systemic diseases, or with co-administration of CYP3A enzyme-dependent drugs.Correspondence to:
Zhongwei Cheng, MD
Department of Cardiology
Peking Union Medical College Hospital
Beijing 100730, China
Email: [email protected]

Abstract

Nieren- und Hochdruckkrankheiten, Jahrgang 44, Nr. 11/2015, S. 491–492

Blockade von Cathepsin S – ein neuer Therapieansatz der Lupus-Nephritis

M. Tatò¹, S.V. Kumar¹, Y. Liu¹, S.R. Mulay¹, J. Eberhard¹, G. Hartmann² und H.-J. Anders¹

¹Nephrologisches Zentrum, Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, ²Pharma Forschung und Entwicklung, Hoffman La Roche, Basel, Schweiz
Correspondence to:
Prof. Dr. med. Hans-Joachim Anders
Nephrologisches Zentrum
Medizinische Klinik und Poliklinik IV
Klinikum der Universität München, Campus Innenstadt
Ziemssenstraße 1
D–80336 München
Email: [email protected]

Abstract

Warum bekommen nicht alle chronisch Niereninsuffiziente Gicht? Untersuchungen zu Zelltod von Neutrophilen und zur Monozytenfunktion

S. Steiger, Q. Ma, J. Desai, Y. Liu, J.F. Grill, A. Rocanin- Arjo, S. Martini, H. Schäfer, J. Lichtnekert, T. Seibt, M. Weidenbusch, T. Sitter und H.J. Anders

Nephrologisches Zentrum, Klinikum der Universität München, München
Correspondence to:
Dr. Stefanie Steiger, PhD
Klinikum der Universität München
Medizinische Klinik und Poliklinik IV der LMU
Ziemssenstraße 1
80336 München
Email: [email protected]

Shopping Overview
Type	Qtty	Discount	VAT	Price
Your basket is empty

View Cart

Search Results

Shopping Overview

Send us an E-Mail